Search results
Showing 1 to 2 of 2 results for atogepant
Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.
170,000 people in England to have further treatment choice for preventing migraine attacks
In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to 170,000 people to choose it on the NHS in England.